Key statistics
As of last trade, Immunitybio Inc (26CA:FRA) traded at 4.85, 73.38% above the 52 week low of 2.80 set on Sep 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.62 |
---|---|
High | 4.85 |
Low | 4.62 |
Bid | 4.81 |
Offer | 4.93 |
Previous close | 4.79 |
Average volume | 6.53k |
---|---|
Shares outstanding | 696.53m |
Free float | 159.61m |
P/E (TTM) | -- |
Market cap | 3.51bn USD |
EPS (TTM) | -0.867 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 18:55 GMT.
More ▼
Press releases
- ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
- ImmunityBio Reports Third-Quarter 2024 Financial Results
- First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
- ImmunityBio to Participate in the Jefferies London Healthcare Conference
- ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
More ▼